Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center

Abemaciclib significantly improves invasive disease-free survival when combined with endocrine therapy in clinical high-risk patients with HR+/Her2− early breast cancer (eBC). The objective of the following study was to model how many patients with eBC would be available for adjuvant treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales: Dannehl, Dominik, Volmer, Lea L., Weiss, Martin, Matovina, Sabine, Grischke, Eva-Maria, Oberlechner, Ernst, Seller, Anna, Walter, Christina B., Hahn, Markus, Engler, Tobias, Brucker, Sara Y., Hartkopf, Andreas D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951288/
https://www.ncbi.nlm.nih.gov/pubmed/35330381
http://dx.doi.org/10.3390/jpm12030382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8951288/
https://www.ncbi.nlm.nih.gov/pubmed/35330381
http://dx.doi.org/10.3390/jpm12030382

Ejemplares similares